| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Aviad Friedman last filed a Form 4 in January 2022, as Director at ORMP. Aviad Friedman's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Aviad Friedman has 5 Form 4 filings on record from February 2017 to January 2022, all as Director at Oramed Pharmaceuticals (ORMP), 2017–2022.
The 9 reported transactions were 4 option or other derivative awards, 2 gifts, 2 open-market purchases and 1 stock award.
Counted by filing, the open-market trades come to 1 purchase worth about $12K and no sales.
The only open-market purchase was 2,500 shares of ORMP at an average $4.95 on August 9, 2018, about $12K.
Shares as reported in the last Form 4 for each company; the most recent is from January 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 9, 2018 | ORMP Oramed Pharmaceuticals Inc. | Director | Buy | 2,500 | $4.95 | $12,370.00 | +25.8% |